SPP1 and Alzheimer disease: The FDA-approved anti-AD drug glatiramer acetate increases the plasma levels of OPN, and therefore promotes a macrophage phenotype that is highly phagocytic of Aβ and anti-inflammatory (Rentsendorj et al., 2018).